VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Be healthy for their age group with or without     │ Be healthy for their age group with or without     │     100 │
│ medication on the basis of physical examination,   │ medication on the basis of physical examination,   │         │
│ medical history, vital signs, and 12-lead          │ medical history, vital signs, and 12-lead          │         │
│ electrocardiogram (ECG) performed at Screening or  │ electrocardiogram (ECG) performed at Screening or  │         │
│ admission. Minor deviations in ECG, which are not  │ admission. Minor deviations in ECG, which are not  │         │
│ considered to be of clinical significance to the   │ considered to be of clinical significance to the   │         │
│ investigator, are acceptable                       │ investigator, are acceptable                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be healthy on the basis of clinical laboratory     │ Be healthy on the basis of clinical laboratory     │     100 │
│ tests performed at Screening. If the results of    │ tests performed at Screening. If the results of    │         │
│ the serum chemistry panel \[including liver        │ the serum chemistry panel [including liver         │         │
│ enzymes\], hematology, or urinalysis are outside   │ enzymes], hematology, or urinalysis are outside    │         │
│ the normal reference ranges, the participant may   │ the normal reference ranges, the participant may   │         │
│ be included only if the investigator judges the    │ be included only if the investigator judges the    │         │
│ abnormalities or deviations from normal to be not  │ abnormalities or deviations from normal to be not  │         │
│ clinically significant. This determination must be │ clinically significant. This determination must be │         │
│ recorded in the participants' source documents and │ recorded in the participants' source documents and │         │
│ initialed by the investigator                      │ initialed by the investigator                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Men who are sexually active with a woman of        │ Men who are sexually active with a woman of        │     100 │
│ childbearing potential and have not had a          │ childbearing potential and have not had a          │         │
│ vasectomy must agree to use a barrier method of    │ vasectomy must agree to use a barrier method of    │         │
│ birth control for example, either condom with      │ birth control for example, either condom with      │         │
│ spermicidal foam/gel/film/cream/suppository or     │ spermicidal foam/gel/film/cream/suppository or     │         │
│ partner with occlusive cap (diaphragm or           │ partner with occlusive cap (diaphragm or           │         │
│ cervical/vault caps) with spermicidal              │ cervical/vault caps) with spermicidal              │         │
│ foam/gel/film/cream/suppository, and all men must  │ foam/gel/film/cream/suppository, and all men must  │         │
│ also not donate sperm during the study and for 3   │ also not donate sperm during the study and for 3   │         │
│ months after receiving the last dose of study      │ months after receiving the last dose of study      │         │
│ drug. In addition, their female partners should    │ drug. In addition, their female partners should    │         │
│ also use an appropriate method of birth control    │ also use an appropriate method of birth control    │         │
│ for at least the same duration                     │ for at least the same duration                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants' must have signed an informed consent │ Participants' must have signed an informed consent │     100 │
│ document indicating that they understand the       │ document indicating that they understand the       │         │
│ purpose of and procedures required for the study   │ purpose of and procedures required for the study   │         │
│ and are willing to participate in the study        │ and are willing to participate in the study        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant has a clinically significant abnormal  │ Participant has a clinically significant abnormal  │     100 │
│ physical examination, vital signs or 12 lead ECG   │ physical examination, vital signs or 12 lead ECG   │         │
│ (including QTc greater than (\>) 450msec, Left     │ (including QTc greater than (>) 450msec, Left      │         │
│ Bundle Branch Block, permanent pacemaker or        │ Bundle Branch Block, permanent pacemaker or        │         │
│ implantable cardioverter defibrillator) at         │ implantable cardioverter defibrillator) at         │         │
│ Screening or admission                             │ Screening or admission                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant has a history of or current liver or   │ Participant has a history of or current liver or   │     100 │
│ renal insufficiency; significant cardiac,          │ renal insufficiency; significant cardiac,          │         │
│ vascular, pulmonary, gastrointestinal, endocrine,  │ vascular, pulmonary, gastrointestinal, endocrine,  │         │
│ neurologic, hematologic, rheumatologic,            │ neurologic, hematologic, rheumatologic,            │         │
│ psychiatric, or metabolic disturbances             │ psychiatric, or metabolic disturbances             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any prescription or over-the-counter        │ Use of any prescription or over-the-counter        │     100 │
│ medication, herbal medication, vitamins, or        │ medication, herbal medication, vitamins, or        │         │
│ mineral supplements within 14 days prior to study  │ mineral supplements within 14 days prior to study  │         │
│ drug administration (not including paracetamol).   │ drug administration (not including paracetamol).   │         │
│ Medication for chronic use in age related disease  │ Medication for chronic use in age related disease  │         │
│ will be allowed after approval by both the         │ will be allowed after approval by both the         │         │
│ investigator and to the sponsor. No change in dose │ investigator and to the sponsor. No change in dose │         │
│ or regimen will be permitted during the study that │ or regimen will be permitted during the study that │         │
│ is, from the Screening visit until the follow-up   │ is, from the Screening visit until the follow-up   │         │
│ visit                                              │ visit                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant has a history of spontaneous,          │ Participant has a history of spontaneous,          │     100 │
│ prolonged or severe bleeding of unclear origin     │ prolonged or severe bleeding of unclear origin     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant has a history of epilepsy or fits or   │ Participant has a history of epilepsy or fits or   │     100 │
│ unexplained black-outs other than vasovagal        │ unexplained black-outs other than vasovagal        │         │
│ collapse                                           │ collapse                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Body mass index (BMI; weight                       │ Body mass index (BMI; weight                       │      97 │
│ \[kilogram(kg)\]/height\^2 \[meter square          │ [kilogram(kg)]/height^2 [meter square (m^2)])      │         │
│ (m\^2)\]) between 18 and 30 kg/m\^2, (inclusive)   │ between 18 and 30 kg/m^2, (inclusive)              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                  │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════╪═════════╡
│ Must be MALE                      │ Participant has a history of spontaneous,      │      12 │
│                                   │ prolonged or severe bleeding of unclear origin │         │
├───────────────────────────────────┼────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 55 Years │ Participant has a history of spontaneous,      │      30 │
│                                   │ prolonged or severe bleeding of unclear origin │         │
├───────────────────────────────────┼────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years │ Participant has a history of spontaneous,      │      30 │
│                                   │ prolonged or severe bleeding of unclear origin │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 82.23076923076923
OverAll Ratio: 90.11538461538461
